BR112020023946A2 - composto heterocíclico, e, composição farmacêutica. - Google Patents

composto heterocíclico, e, composição farmacêutica. Download PDF

Info

Publication number
BR112020023946A2
BR112020023946A2 BR112020023946-1A BR112020023946A BR112020023946A2 BR 112020023946 A2 BR112020023946 A2 BR 112020023946A2 BR 112020023946 A BR112020023946 A BR 112020023946A BR 112020023946 A2 BR112020023946 A2 BR 112020023946A2
Authority
BR
Brazil
Prior art keywords
pyrazin
pyrido
bromo
imidazo
mmol
Prior art date
Application number
BR112020023946-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Kwang Seok Ko
Soon Ok Lee
Young Jin Kwon
Jee Hun YUN
Nam Chul Cho
Ji Eun Lee
Jung Sook Kim
Original Assignee
C&C Research Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Research Laboratories filed Critical C&C Research Laboratories
Publication of BR112020023946A2 publication Critical patent/BR112020023946A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112020023946-1A 2018-05-31 2019-05-31 composto heterocíclico, e, composição farmacêutica. BR112020023946A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0062254 2018-05-31
KR20180062254 2018-05-31
PCT/KR2019/006553 WO2019231270A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (1)

Publication Number Publication Date
BR112020023946A2 true BR112020023946A2 (pt) 2021-02-23

Family

ID=68698381

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020023946-1A BR112020023946A2 (pt) 2018-05-31 2019-05-31 composto heterocíclico, e, composição farmacêutica.

Country Status (12)

Country Link
US (1) US20210198259A1 (cg-RX-API-DMAC7.html)
EP (1) EP3807282A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021525738A (cg-RX-API-DMAC7.html)
KR (1) KR102344295B1 (cg-RX-API-DMAC7.html)
CN (1) CN112204032A (cg-RX-API-DMAC7.html)
AU (1) AU2019279421A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023946A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098825A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011955A (cg-RX-API-DMAC7.html)
SG (1) SG11202010985TA (cg-RX-API-DMAC7.html)
TW (1) TW202021969A (cg-RX-API-DMAC7.html)
WO (1) WO2019231270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE358395B (cg-RX-API-DMAC7.html) * 1967-09-27 1973-07-30 Siegfried Ag
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TW201206936A (en) * 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
CN103889986B (zh) * 2011-09-30 2017-07-21 C&C新药研究所 新杂环衍生物及其应用
WO2014152029A2 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
US10407423B2 (en) * 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
JP7212612B2 (ja) * 2016-07-28 2023-01-25 プロメガ コーポレイション セレンテラジン類縁体

Also Published As

Publication number Publication date
EP3807282A4 (en) 2022-03-02
US20210198259A1 (en) 2021-07-01
KR102344295B1 (ko) 2021-12-29
CA3098825A1 (en) 2019-12-05
SG11202010985TA (en) 2020-12-30
EP3807282A1 (en) 2021-04-21
TW202021969A (zh) 2020-06-16
KR20190137013A (ko) 2019-12-10
CN112204032A (zh) 2021-01-08
JP2021525738A (ja) 2021-09-27
MX2020011955A (es) 2021-01-15
AU2019279421A1 (en) 2020-12-03
WO2019231270A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US12247027B2 (en) P2X7 modulators
US10077243B2 (en) Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN107660205B (zh) 作为lsd1抑制剂的杂环化合物
US10513523B2 (en) Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
WO2014133022A1 (ja) テトラヒドロイミダゾ[1,5-d][1,4]オキサゼピン誘導体
TW202104223A (zh) 磷脂醯肌醇3-激酶抑制劑
KR20220079919A (ko) 헤테로시클릭 rip1 억제 화합물
EP2493895A1 (en) N-containing heteroaryl derivatives as jak3 kinase inhibitors
US20220315597A1 (en) Tricyclic compounds and their use
CA2848154A1 (en) Novel heterocyclic derivatives and their uses
KR102344295B1 (ko) 헤테로사이클 유도체 및 이의 용도
WO2019031990A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
BR112019017058A2 (pt) compostos como inibidores de pde1, composição farmacêutica e uso dos mesmos
JP7551607B2 (ja) アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
JP2021525738A5 (cg-RX-API-DMAC7.html)
HK40034987A (en) Heterocyclic derivatives and use thereof
CN120441568A (zh) 作为Cbl-b抑制剂的化合物及其应用
BR112020018983A2 (pt) Inibidores de canal receptor de potencial transitório de oxadiazol
HK1172327B (en) N-containing heteroaryl derivatives as jak3 kinase inhibitors
BR122020017743B1 (pt) Processo para fabricação de uma composição farmacêutica e uso de uma composição farmacêutica
CN105579459A (zh) 四并环类间变性淋巴瘤激酶抑制剂
BR112014010459B1 (pt) Compostos e composição farmacêutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements